FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts

Group 3 tumors account for 28% of medulloblastomas and have the worst prognosis. FTY720, an immunosuppressant currently approved for treatment of multiple sclerosis, has shown antitumor effects in several human cancer cell lines. We hypothesized that treatment with FTY720 (fingolimod) would decrease...

Descripción completa

Detalles Bibliográficos
Autores principales: Garner, Evan F., Williams, Adele P., Stafman, Laura L., Aye, Jamie M., Mroczek-Musulman, Elizabeth, Moore, Blake P., Stewart, Jerry E., Friedman, Gregory K., Beierle, Elizabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932040/
https://www.ncbi.nlm.nih.gov/pubmed/29720672
http://dx.doi.org/10.1038/s41598-018-25263-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932040/
https://www.ncbi.nlm.nih.gov/pubmed/29720672
http://dx.doi.org/10.1038/s41598-018-25263-5

Ejemplares similares